Hi Maryann, excellent advice on PV. According to latest research Anagrelide is not superior to hydroxyurea in PV. www.nejm.org/doi/full/10.1056/NEJMoa04380
P-32 is limited in use to the extreme elderly due to approximate 10 year latency towards leukemia conversion risk. Interferon alpha 2b has been effective in reducing clinical symptoms and in reducing JAK2, and it may retard advancement in those susceptible towards developing agnogenic myeloid metaplasia with myelofibrosis, approximately 30-50% of patients followed for about 20 years. Try this site for great info on "itching" in PV. It is from one of our subscribers at www.mpdsupport.org, about 3,000 of us, since 1994. We have a free daily email digest. Robert http://pauljnm.net/pv.htm and http://pauljnm.net/itch_fix.htm
Comment Reply
Hi Maryann, excellent advice on PV. According to latest research Anagrelide is not superior to hydroxyurea in PV. www.nejm.org/doi/full/10.1056/NEJMoa04380
March 25, 2011 - 6:09pmP-32 is limited in use to the extreme elderly due to approximate 10 year latency towards leukemia conversion risk. Interferon alpha 2b has been effective in reducing clinical symptoms and in reducing JAK2, and it may retard advancement in those susceptible towards developing agnogenic myeloid metaplasia with myelofibrosis, approximately 30-50% of patients followed for about 20 years. Try this site for great info on "itching" in PV. It is from one of our subscribers at www.mpdsupport.org, about 3,000 of us, since 1994. We have a free daily email digest. Robert http://pauljnm.net/pv.htm and http://pauljnm.net/itch_fix.htm
This Comment
Reply